Hayward, CA-based Anthera Pharmaceuticals (NASDAQ: [[ticker:ANTH]]) said today it raised $47 million through a stock offering, after deducting expenses. The company sold about 6.7 million shares of stock at $7.50 apiece, and granted its underwriters a 30-day option to buy another 1 million shares. Citi, Leerink Swann, and Canaccord Genuity managed the offering.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
